Pharmaceuticals, Biotechnology & Life Sciences

Positive CHMP recommendation for Novo Nordisk’s Wegovy 7.2 mg pen could boost EU approval and investor confidence, promising a 20.7 % weight‑loss benefit and AI‑driven growth.

Glenmark Pharmaceuticals’ high‑margin biologics pipeline faces regulatory, pricing and competition hurdles, so investors eye its June earnings call for a clear growth path amid a lofty P/E.

InflaRx NV faces steep financial hurdles as a biotech pioneer developing monoclonal antibodies for inflammatory diseases, with a negative P/E and volatile stock, challenging investor confidence.

Discover why Pfizer may be undervalued—deep dive into its strong cash flow, late‑stage oncology pipeline, AI partnerships, and upside potential.

Amarin Corporation PLC

Breakthrough Chemistry Inc’s volatile stock, low market cap, and negative P/E reveal serious profitability issues, urging investors to scrutinize its future viability in pharma.

Satellos Bioscience Inc. updates shareholders on its AGM and governance while advancing skeletal muscle regeneration therapies.

Teva’s EMA approval of its olanzapine long‑acting injectable expands its portfolio into high‑margin psychiatry, boosting revenue prospects and positioning the company for global growth.

Hyperliquid Strategies surges on SEC tokenized‑stock buzz, 24/7 futures, and $52M institutional buy‑in—can the DeFi newcomer sustain its meteoric rise amid regulatory scrutiny?

Valneva SE, a French biotech leader, pioneers vaccine development with proprietary EB66 cells and IC31 adjuvant, tackling diseases from Japanese encephalitis to Zika.